Published in J Immunol on September 15, 2008
Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol (2009) 2.31
piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther (2010) 1.64
Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin Cancer Res (2011) 1.13
Tumor regulatory T cells potently abrogate antitumor immunity. J Immunol (2009) 1.09
In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy. J Immunol (2009) 1.08
Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity. J Immunol (2011) 1.04
A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice. J Immunol (2012) 0.94
Combination of chemotherapy and immunotherapy for colon cancer in China: a meta-analysis. World J Gastroenterol (2014) 0.90
Bystander activation and anti-tumor effects of CD8+ T cells following Interleukin-2 based immunotherapy is independent of CD4+ T cell help. PLoS One (2014) 0.88
Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies. Front Immunol (2013) 0.84
Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer. Cancer Immunol Immunother (2011) 0.81
Therapeutic immunity by adoptive tumor-primed CD4(+) T-cell transfer in combination with in vivo GITR ligation. Mol Ther (2009) 0.81
Enhanced response of T cells from murine gammaherpesvirus 68-infected mice lacking the suppressor of T cell receptor signaling molecules Sts-1 and Sts-2. PLoS One (2014) 0.78
Treatment with targeted vesicular stomatitis virus generates therapeutic multifunctional anti-tumor memory CD4 T cells. Cancer Gene Ther (2012) 0.78
Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4(+) T cells combined with agonist α-GITR mAb promotes durable CD8(+) T-cell-dependent antitumor immunity. Oncoimmunology (2017) 0.75
Tolerance, danger, and the extended family. Annu Rev Immunol (1994) 14.94
In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity (2002) 14.57
Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol (2006) 9.42
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 6.95
Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 6.81
Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol (2004) 5.80
Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol (2003) 5.47
Helping the CD8(+) T-cell response. Nat Rev Immunol (2004) 4.90
Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med (1999) 3.29
A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis (1999) 2.93
CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med (1999) 2.77
CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood (2007) 2.68
DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol (2000) 2.65
CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci U S A (1999) 2.60
Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother (2005) 2.56
Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes. J Exp Med (1981) 2.50
CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res (2003) 2.40
Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J Immunol (2006) 2.40
CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest (1997) 2.39
Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res (2008) 2.38
IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med (2007) 2.23
Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med (2006) 2.10
Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J Immunol (2000) 2.06
Role of IFN-gamma in induction of Foxp3 and conversion of CD4+ CD25- T cells to CD4+ Tregs. J Clin Invest (2006) 2.02
Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res (2006) 1.97
Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol (2002) 1.88
Vaccines for tumour prevention. Nat Rev Cancer (2006) 1.87
HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res (2000) 1.86
Human tumor antigens for cancer vaccine development. Immunol Rev (1999) 1.76
CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol (2003) 1.61
IFN-gamma can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen. J Immunol (2000) 1.56
CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes. J Exp Med (2000) 1.48
Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol (2000) 1.47
Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J Immunol (2004) 1.29
CD4+ T lymphocytes: a critical component of antitumor immunity. Cancer Invest (2005) 1.14
Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood (2002) 1.10
Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection. Blood (2005) 1.10
Interferon-gamma-dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma. Cancer Res (2002) 1.09
Enhanced immunity by NeuEDhsp70 DNA vaccine Is needed to combat an aggressive spontaneous metastatic breast cancer. Mol Ther (2005) 1.06
Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression. Cancer Res (2002) 1.05
Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent. J Immunol (2004) 1.04
Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity. Cancer Res (2005) 1.04
Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J Immunol (2004) 1.01
T helper lymphocytes rescue CTL from activation-induced cell death. J Immunol (2006) 1.00
Regulatory T cells inhibit Fas ligand-induced innate and adaptive tumour immunity. Eur J Immunol (2007) 0.96
Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo. J Immunol (2000) 0.94
Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J Immunol (1998) 0.94
The role of CD4+ T cell help in cancer immunity and the formulation of novel cancer vaccines. Cancer Immunol Immunother (2006) 0.92
Tumor HLA-DR expression linked to early intrahepatic recurrence of hepatocellular carcinoma. Int J Cancer (2005) 0.91
Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells. Cancer Res (2004) 0.89
Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells. J Immunol (1985) 0.87
An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy. Cancer Res (2006) 0.80
CD40 ligation restores cytolytic T lymphocyte response and eliminates fibrosarcoma in the peritoneum of mice lacking CD4+ T cells. Cancer Immunol Immunother (2006) 0.78
Essential roles of tumor-derived helper T cell epitopes for an effective peptide-based tumor vaccine. Cancer Immun (2003) 0.77
Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood (2004) 3.68
Internalization of circulating apoptotic cells by splenic marginal zone dendritic cells: dependence on complement receptors and effect on cytokine production. Blood (2002) 2.02
Ebola virus VP40 late domains are not essential for viral replication in cell culture. J Virol (2005) 1.97
Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity (2006) 1.95
Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol (2007) 1.60
CD4+ T cell responses elicited by different subsets of human skin migratory dendritic cells. J Immunol (2005) 1.52
Neurokinin-1 receptor agonists bias therapeutic dendritic cells to induce type 1 immunity by licensing host dendritic cells to produce IL-12. Blood (2013) 1.48
Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol (2005) 1.39
Changing paradigms in cutaneous immunology: adapting with dendritic cells. J Invest Dermatol (2005) 1.35
Association between BMI and metabolic syndrome and adenomatous colonic polyps in Korean men. Obesity (Silver Spring) (2008) 1.25
AAP1 transports uncharged amino acids into roots of Arabidopsis. Plant J (2007) 1.20
Endothelia of Schlemm's canal and trabecular meshwork: distinct molecular, functional, and anatomic features. Am J Physiol Cell Physiol (2003) 1.19
Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children. HIV Med (2011) 1.14
Granzyme B activates procaspase-3 which signals a mitochondrial amplification loop for maximal apoptosis. J Cell Biol (2003) 1.13
Tumor regulatory T cells potently abrogate antitumor immunity. J Immunol (2009) 1.09
Enhanced immunity by NeuEDhsp70 DNA vaccine Is needed to combat an aggressive spontaneous metastatic breast cancer. Mol Ther (2005) 1.06
Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity. J Immunol (2011) 1.04
Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity. Cancer Res (2005) 1.04
Induction of therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine. Hum Gene Ther (2005) 1.04
Verification by polymerase chain reaction of vertical transmission of Theileria sergenti in cows. Can J Vet Res (2003) 0.97
Lentivirus as a potent and mechanistically distinct vector for genetic immunization. Curr Opin Mol Ther (2007) 0.97
Immunostimulation of dendritic cells by cationic liposomes. Mol Membr Biol (2006) 0.96
IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors. J Immunother (2009) 0.92
Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. Cancer Res (2007) 0.92
Recombinant lentivector as a genetic immunization vehicle for antitumor immunity. Expert Rev Vaccines (2007) 0.90
Disrupted homeostasis of Langerhans cells and interdigitating dendritic cells in monkeys with AIDS. Blood (2002) 0.90
Resistance of Sézary cells to TNF-α-induced apoptosis is mediated in part by a loss of TNFR1 and a high level of the IER3 expression. Exp Dermatol (2012) 0.89
Phagocytosis induces lysosome remodeling and regulated presentation of particulate antigens by activated dendritic cells. J Immunol (2006) 0.88
An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD). Ther Adv Endocrinol Metab (2011) 0.86
DNA immunisation: altering the cellular localisation of expressed protein and the immunisation route allows manipulation of the immune response. Vaccine (2004) 0.85
Vaccination with photodynamic therapy-treated macrophages induces highly suppressive T-regulatory cells. Photodermatol Photoimmunol Photomed (2011) 0.85
Role of infectious agents in cutaneous T-cell lymphoma: facts and controversies. Clin Dermatol (2013) 0.84
Comparative proteomic analysis reveals unique tumor protein composition among the melanoma subtypes pure desmoplastic and superficial spreading. Melanoma Res (2014) 0.84
Reconstitution of galectin-3 alters glutathione content and potentiates TRAIL-induced cytotoxicity by dephosphorylation of Akt. Exp Cell Res (2003) 0.83
Highly efficient expression of transgenic proteins by naked DNA-transfected dendritic cells through terminal differentiation. Blood (2003) 0.83
Low extracellular pH augments TRAIL-induced apoptotic death through the mitochondria-mediated caspase signal transduction pathway. Exp Cell Res (2004) 0.82
Chemically and biologically synthesized CPP-modified gelonin for enhanced anti-tumor activity. J Control Release (2013) 0.81
Antiretroviral Drug Resistance Among Children and Youth in the United States With Perinatal HIV. Clin Infect Dis (2016) 0.81
Dissolvable microneedle arrays for intradermal delivery of biologics: fabrication and application. Pharm Res (2013) 0.81
Acitretin for treatment of EGFR inhibitor-induced cutaneous toxic effects. Arch Dermatol (2008) 0.81
Therapeutic immunity by adoptive tumor-primed CD4(+) T-cell transfer in combination with in vivo GITR ligation. Mol Ther (2009) 0.81
Interaction effect of serum 25-hydroxyvitamin D levels and CYP1A1, CYP1B1 polymorphisms on blood pressure in an elderly population. J Hypertens (2015) 0.81
Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccine-induced prophylactic and therapeutic antitumor immunity. Mol Ther (2011) 0.81
Reconstitution of caspase-3 confers low glucose-enhanced tumor necrosis factor-related apoptosis-inducing ligand cytotoxicity and Akt cleavage. Clin Cancer Res (2004) 0.81
Lipid-protamine-DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses. Mol Ther (2003) 0.81
Induction of T cell immunity by cutaneous genetic immunization with recombinant lentivector. Immunol Res (2006) 0.80
Human beta-defensin 3 induces maturation of human langerhans cell-like dendritic cells: an antimicrobial peptide that functions as an endogenous adjuvant. J Invest Dermatol (2012) 0.80
Enhancement of metabolic oxidative stress-induced cytotoxicity by the thioredoxin inhibitor 1-methylpropyl 2-imidazolyl disulfide is mediated through the ASK1-SEK1-JNK1 pathway. Mol Pharmacol (2002) 0.79
A 'good death' for tumor immunology. Nat Med (2007) 0.79
Human cytomegalovirus induces apoptosis in promonocyte THP-1 cells but not in promyeloid HL-60 cells. Virus Res (2003) 0.76
Novel therapeutic combination demonstrates more than additive effects in cutaneous T-cell lymphoma. Leuk Lymphoma (2015) 0.75
COOPERATION MAINTAINED BY FITNESS ADJUSTMENT. Evol Ecol Res (2007) 0.75
Utilization of hierarchical, stochastic relationship modeling for Hangul character recognition. IEEE Trans Pattern Anal Mach Intell (2004) 0.75
Quantitative correlation between infectivity and Gp120 density on HIV-1 virions revealed by optical trapping virometry. J Biol Chem (2017) 0.75
Effects of personality traits on collaborative performance in problem-based learning tutorials. Saudi Med J (2017) 0.75
High performing smart electrochromic device based on honeycomb nanostructured h-WO3 thin films: hydrothermal assisted synthesis. Dalton Trans (2015) 0.75
Injury risk behaviours among young Asian New Zealanders: a national survey of secondary school students. Aust N Z J Public Health (2008) 0.75
A Fast Finite-Time Neural Network Control of Stochastic Nonlinear Systems. IEEE Trans Neural Netw Learn Syst (2022) 0.75